Biochemical and immunological status following gene therapy and PEG-ADA therapy for adenosine deaminase (ADA) deficiency.
Fairbanks
L D
LD
Molecular Immunology Unit, UMDS Guy's Hospital, London, GB.
Simmonds
H A
HA
Hoogerbrugge
P M
PM
van Beusechem
V W
VW
Valerio
D
D
Moseley
A
A
Levinsky
R J
RJ
Gaspar
H B
HB
Morgan
G
G
D000243:Adenosine Deaminase / Q000096:biosynthesis / Q000172:deficiency* / Q000627:therapeutic use*; D005260:Female; D015316:Genetic Therapy; D006412:Hematopoietic Stem Cells; D006801:Humans; D007223:Infant; D011994:Recombinant Proteins / Q000096:biosynthesis; D016511:Severe Combined Immunodeficiency / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D014162:Transfection
D011994:Recombinant Proteins; D000243:Adenosine Deaminase; C051409:pegademase bovine